Riskpilot← Back to searchSign inGet full accessLeif Anderbergs Läkarkonsult AB
ABActiveOrg 5567423925Tornfalksvägen 3Medical specialists activities · NACE 8622Est. 20071 employees
Revenue 2025
SEK 429K
-74% vs 2024
EBITDA margin
45.0%
-69% vs 2024
Equity ratio
91.3%
Financial strength
Net profit 2025
SEK -539K
-246% vs 2024
| Revenue | SEK 429K | -74% |
| EBITDA | SEK 193K | -69% |
| Net profit | SEK -539K | -246% |
| Total assets | SEK 1,4M | -40% |
| Equity | SEK 1,3M | -36% |
| Employees | 1 | — |
Legal name
Leif Anderbergs Läkarkonsult AB
Org number
5567423925
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
9 november 2007
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av suppleanten Styrelsen ska bestå av 1 styrelseledamot och 1 styrelsesuppleant.
Company purpose
Föremålet för bolagets verksamhet är konsultverksamhet inom sjukvård, äga och förvalta fastigheter och värdepapper, och därmed förenlig verksamhet.
Address
Tornfalksvägen 3
Email
leif.anderberg@me.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 896 | 2 127 | 2 389 | 1 654 | 429 |
| Staff expenses | — | −14 | −997 | −729 | — |
| EBITDA | −1 587 | 1 745 | 1 244 | 616 | 193 |
| Depreciation & amort. | −121 | −117 | −130 | −130 | −87 |
| EBIT | −1 708 | 1 628 | 1 114 | 486 | 106 |
| Net financials | — | −0 | 8 | −15 | 630 |
| Profit before tax | −1 645 | 1 628 | 1 122 | 472 | −516 |
| Tax | −0 | — | −229 | −101 | −23 |
| Net profit | −1 645 | 1 628 | 893 | 370 | −539 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 505 | 1 852 | 2 484 | 2 400 | 1 443 |
| Equity | 1 964 | 1 792 | 1 886 | 2 056 | 1 317 |
| Long-term debt | 0 | — | — | — | 0 |
| Short-term debt | 541 | 60 | 599 | 345 | 126 |
| Total debt | 541 | 60 | 599 | 345 | 126 |
EBITDA margin
45.0%
This company
15.8%
Market median
+185% vs market
20212025
Equity ratio
91.3%
This company
38.2%
Market median
+139% vs market
20212025
Return on equity
-40.9%
This company
18.4%
Market median
-322% vs market
20212025
Net profit margin
-125.6%
This company
8.1%
Market median
-1651% vs market
20212025
Asset turnover
0.30×
This company
1.12×
Market median
-73% vs market
20212025
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
LA Chief Executive Officer | Chief Executive Officer | 2022 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Leif Anderbergs Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif-Göran Anderberg | Chief Executive Officer | 0 companies |
| Karin Josefin Anderberg | Deputy Board Member | 0 companies |
| Karin Josefin Anderberg | Deputy Board Member | 0 companies |